Across TCGA pan-cancer cohorts, THEM4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated THEM4 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher THEM4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated THEM4 expression acts as an unfavorable survival marker.
SKCM are the cancer types where THEM4 Mutation most reproducibly stratifies survival.